A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.
about
Intracellular Delivery of Proteins with Cell-Penetrating Peptides for Therapeutic Uses in Human DiseaseP-cadherin and the journey to cancer metastasisOvercoming drug resistance in multi-drug resistant cancers and microorganisms: a conceptual frameworkBacterial proteins and peptides in cancer therapy: today and tomorrowGlioblastoma multiforme: novel therapeutic approachesTumor profiling of gastric and esophageal carcinoma reveal different treatment optionsPatent controversies and court cases: cancer diagnosis, therapy and prevention.p28, a first in class peptide inhibitor of cop1 binding to p53.Gene mutations and actionable genetic lesions in mantle cell lymphoma.Bacterial Carriers for Glioblastoma TherapyTherapeutic potential of cell-penetrating peptides.Insights into the molecular mechanisms of action of bioportides: a strategy to target protein-protein interactions.Strategies to stabilize cell penetrating peptides for in vivo applications.Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.Structural studies on Laz, a promiscuous anticancer Neisserial protein.Enhanced serum proteolysis resistance of cell-penetrating peptides.Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review.Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.Impairment of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK inhibitors.Discovery of Azurin-Like Anticancer Bacteriocins from Human Gut Microbiome through Homology Modeling and Molecular Docking against the Tumor Suppressor p53Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion.Bacterial azurin in potential cancer therapyBacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy.Surface Plasmon Resonance Sensing of Biorecognition Interactions within the Tumor Suppressor p53 Network.TAT-MTS-MCM fusion proteins reduce MMA levels and improve mitochondrial activity and liver function in MCM-deficient cells.The Current Role of Cell-Penetrating Peptides in Cancer Therapy.Regulation of human T cell responses by dNP2-ctCTLA-4 inhibits human skin and microvessel graft rejectionAzurin interaction with the lipid raft components ganglioside GM-1 and caveolin-1 increases membrane fluidity and sensitivity to anti-cancer drugs
P2860
Q26767093-65757FE3-66F0-475D-A88C-DF91271A4911Q26781906-BF1E8309-ADE3-42A9-91FE-2C92FB4BE9DFQ27000458-C8A1B78F-1377-4199-BF74-747AA64E2252Q34075830-511C8048-1FA4-4C52-94FB-05B618A97252Q35825491-0FFADF9E-8203-44CA-ADF9-5CE37A6A3DC7Q36214575-21662A2C-0AA9-48A8-81BD-12A2AD68BCCBQ36384313-CC879317-F265-4372-97A0-97F39A17995CQ36959166-52A55689-F91E-4E92-A52F-6F9475CCF48FQ37629080-99406D07-8F5A-4E08-A390-7B95E0AFF364Q37718566-2B678246-C66D-42F5-8F3A-34EFC1C8A236Q38104407-74CD4E3E-E038-42C4-9B86-78B3E0713199Q38563691-EE36CA95-B21C-44F0-A66E-AA079601469BQ38602460-22DD0E7D-3FAC-4D81-BF9E-EC51D1F871B0Q38710688-FB95E7F8-27D5-4CB7-AED7-2BD9AADC8F02Q38906195-C50E1C8E-DCDC-483F-B550-B4945AFA50E4Q38908688-1103219B-7D20-43D6-A83D-9510DF34E7F6Q38948352-1C7B0782-0084-4228-9F37-80AF27785339Q41138860-ACC5A228-5CCC-45C6-AE4D-FDF965DAB62DQ41249331-E4F6557A-2B2C-4512-8EA7-0A294F0C0BDDQ41573303-48F30505-07E5-4493-9B08-6BB5C54A900CQ41876620-216D28CC-579A-4D1E-85F5-16678B056FC8Q42258585-73255C6A-7B08-4DA5-8FA5-D276DC3B1224Q46299094-F1D1669F-3683-40CC-8136-55289F174B08Q47109687-4D8F2DBC-F402-4814-BA70-9016E8FAC8A5Q47266824-B4F6F74D-F55E-4481-B3D6-FA6D18ED7A65Q52450404-F6EB3582-613D-4825-AB48-485F88340D1AQ56871235-48E20011-9A45-4706-8390-0A636756B7F7Q58884356-4DA63E03-5091-41E6-8504-A02E298A3B0D
P2860
A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A first-in-class, first-in-hum ...... s with advanced solid tumours.
@en
type
label
A first-in-class, first-in-hum ...... s with advanced solid tumours.
@en
prefLabel
A first-in-class, first-in-hum ...... s with advanced solid tumours.
@en
P2093
P2860
P356
P1476
A first-in-class, first-in-hum ...... s with advanced solid tumours.
@en
P2093
C Schaeffer
D Majumdar
J M Richards
K Christov
L Rae Bressler
S A Kennedy
T K Das Gupta
P2860
P2888
P304
P356
10.1038/BJC.2013.74
P407
P577
2013-02-28T00:00:00Z